<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131077">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01848977</url>
  </required_header>
  <id_info>
    <org_study_id>H-1302-016-462</org_study_id>
    <nct_id>NCT01848977</nct_id>
  </id_info>
  <brief_title>Comparison of Two Devices Using Near-infra Red Spectroscopy During a Vascular Occlusion Test</brief_title>
  <official_title>Comparison of Two Devices Using Near-infra Red Spectroscopy for the Measurement of Tissue Oxygenation During a Vascular Occlusion Test (INVOS® Versus Inspectra™)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tissue oxygen saturation (StO2) is non-invasively measured using near-infrared spectroscopy,
      by two device, Invos®(somanetics Corporation, USA ) and InSpectra™ (Hutchinson Technology,
      USA). Each probes are attached to both thenar muscles and vascular occlusion test (VOT) is
      performed. The investigators will compare the Invos® data to InSpectra™ to investigate
      whether StO2 by Invos® can substitute for InSpectra™.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>desaturation slope and reoxygenation slope(recovery slope)of VOT</measure>
    <time_frame>8 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>blood pressure, Baseline StO2, minimun StO2, maximum StO2</measure>
    <time_frame>8 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>StO2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>vascular occlusion test</intervention_name>
    <description>Using Invos® probe attacted to one thenar muscle, tissue oxgyenation is measured by VOT.</description>
    <arm_group_label>StO2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>vascular occlusion test</intervention_name>
    <description>Using Inspectra™ probe attacted to another thenar muscle, tissue oxgyenation is measured by VOT.</description>
    <arm_group_label>StO2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy subject

        Exclusion Criteria:

          -  age under 18 years old

          -  with arteriovenous fistula

          -  with peripheral vessel disease

          -  taking vasoactive drug

          -  with a skin ailment

          -  with HTN, DM

          -  with diagnosed heart disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>26 Years</minimum_age>
    <maximum_age>41 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 3, 2013</lastchanged_date>
  <firstreceived_date>April 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jin-Tae Kim</investigator_full_name>
    <investigator_title>Ph.D.</investigator_title>
  </responsible_party>
  <keyword>Measures</keyword>
  <keyword>near-Infrared spectroscopy</keyword>
  <keyword>ischemia</keyword>
  <keyword>reperfusion</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
